Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) have been given an average recommendation of “Moderate Buy” by the twelve analysts that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and ten have issued a buy recommendation on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $33.5909.

A number of brokerages have recently weighed in on ROIV. Piper Sandler reissued an “overweight” rating on shares of Roivant Sciences in a report on Thursday, May 21st. Leerink Partners set a $42.00 target price on Roivant Sciences in a research note on Thursday, May 21st. Jefferies Financial Group restated a “buy” rating on shares of Roivant Sciences in a research note on Tuesday, March 3rd. Citigroup upped their target price on Roivant Sciences from $35.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, May 21st. Finally, TD Cowen upped their target price on Roivant Sciences from $38.00 to $41.00 and gave the stock a “buy” rating in a research note on Thursday, May 21st.

Insider Buying and Selling

In other news, CEO Eric Venker sold 200,000 shares of the company’s stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $30.27, for a total value of $6,054,000.00. Following the sale, the chief executive officer owned 1,613,063 shares in the company, valued at $48,827,417.01. This represents a 11.03% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Matthew Gline sold 289,774 shares of the company’s stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of $29.16, for a total value of $8,449,809.84. Following the completion of the sale, the chief executive officer owned 16,736,116 shares in the company, valued at $488,025,142.56. The trade was a 1.70% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 945,173 shares of company stock worth $27,654,456 over the last ninety days. 10.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Roivant Sciences

A number of hedge funds have recently bought and sold shares of the business. Fifth Third Bancorp boosted its position in Roivant Sciences by 8.7% during the first quarter. Fifth Third Bancorp now owns 4,686 shares of the company’s stock worth $130,000 after purchasing an additional 376 shares in the last quarter. Bessemer Group Inc. boosted its stake in shares of Roivant Sciences by 21.8% in the first quarter. Bessemer Group Inc. now owns 2,465 shares of the company’s stock worth $69,000 after acquiring an additional 441 shares during the last quarter. Fifth Third Wealth Advisors LLC lifted its position in Roivant Sciences by 4.6% during the first quarter. Fifth Third Wealth Advisors LLC now owns 10,166 shares of the company’s stock worth $282,000 after buying an additional 445 shares in the last quarter. Oregon Public Employees Retirement Fund lifted its position in Roivant Sciences by 0.6% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 87,152 shares of the company’s stock worth $1,891,000 after buying an additional 500 shares in the last quarter. Finally, Bank of Montreal Can lifted its position in Roivant Sciences by 1.3% during the fourth quarter. Bank of Montreal Can now owns 40,012 shares of the company’s stock worth $868,000 after buying an additional 516 shares in the last quarter. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Roivant Sciences Stock Performance

Shares of ROIV stock opened at $28.49 on Thursday. The stock’s 50-day simple moving average is $28.78 and its 200-day simple moving average is $25.76. The firm has a market capitalization of $20.49 billion, a PE ratio of -47.48 and a beta of 1.13. Roivant Sciences has a fifty-two week low of $10.70 and a fifty-two week high of $32.79.

Roivant Sciences (NASDAQ:ROIV) last announced its quarterly earnings data on Wednesday, May 20th. The company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.57. The business had revenue of $2.52 million for the quarter, compared to analyst estimates of $3.41 million. Roivant Sciences had a negative return on equity of 20.54% and a negative net margin of 3,629.19%.During the same period in the prior year, the company earned ($0.29) earnings per share. Sell-side analysts forecast that Roivant Sciences will post -1.83 earnings per share for the current year.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.